Results
attention-deficit/hyperactivity disorder, ADHD
Study enrollment included 108 participants, with 107 included in the enrolled safety population and 100 of these in the randomized safety population. A total of 99 participants (AMPH EROS, Participant CharacteristicsValues are shown as ADHD, attention-deficit/hyperactivity disorder; AMPH EROS, amphetamine extended-release oral suspension.